Resverlogix Corp. (TSE:RVX – Get Free Report) shares hit a new 52-week low during trading on Monday . The company traded as low as C$0.04 and last traded at C$0.04, with a volume of 1445 shares changing hands. The stock had previously closed at C$0.05.
Resverlogix Stock Performance
The company has a market cap of C$7.92 million, a price-to-earnings ratio of -1.98 and a beta of 0.71. The company has a debt-to-equity ratio of -10.95, a quick ratio of 0.04 and a current ratio of 0.13. The company has a fifty day moving average of C$0.05 and a two-hundred day moving average of C$0.06.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Resverlogix
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Insider Trades May Not Tell You What You Think
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
